Dataset Information


Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.

ABSTRACT: For Ebola virus (EBOV), 4 different species are known: Zaire, Sudan, Côte d'Ivoire, and Reston ebolavirus. The newly discovered Bundibugyo ebolavirus has been proposed as a 5th species. So far, no cross-neutralization among EBOV species has been described, aggravating progress toward cross-species protective vaccines. With the use of recombinant vesicular stomatitis virus (rVSV)-based vaccines, guinea pigs could be protected against Zaire ebolavirus (ZEBOV) infection only when immunized with a vector expressing the homologous, but not a heterologous, EBOV glycoprotein (GP). However, infection of guinea pigs with nonadapted wild-type strains of the different species resulted in full protection of all animals against subsequent challenge with guinea pig-adapted ZEBOV, showing that cross-species protection is possible. New vectors were generated that contain EBOV viral protein 40 (VP40) or EBOV nucleoprotein (NP) as a second antigen expressed by the same rVSV vector that encodes the heterologous GP. After applying a 2-dose immunization approach, we observed an improved cross-protection rate, with 5 of 6 guinea pigs surviving the lethal ZEBOV challenge if vaccinated with rVSV-expressing SEBOV-GP and -VP40. Our data demonstrate that cross-protection between the EBOV species can be achieved, although EBOV-GP alone cannot induce the required immune response.


PROVIDER: S-EPMC3203393 | BioStudies | 2011-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4629916 | BioStudies
2018-01-01 | S-EPMC6217725 | BioStudies
2016-01-01 | S-EPMC4914957 | BioStudies
2010-01-01 | S-EPMC2873919 | BioStudies
2018-01-01 | S-EPMC5952144 | BioStudies
1000-01-01 | S-EPMC3562844 | BioStudies
2019-01-01 | S-EPMC6825541 | BioStudies
2018-01-01 | S-EPMC5770434 | BioStudies
2017-01-01 | S-EPMC5430516 | BioStudies
2018-01-01 | S-EPMC6217721 | BioStudies